Jorth, P., Manuel, C., McLemore, T., Humphries, R. M., Cole, N. C., Schuetz, A. N., Garica, D., Maldonado, M., Rivero, N., Milesi Galdino, A. C., Celedonio, D., LiPuma, J. J., Green, D. A., Zlosnik, J. E. A., Traczewski, M., & Huse, H. K. (2025). Evaluation of antimicrobial susceptibility testing methods for Burkholderia cepacia complex isolates from people with and without cystic fibrosis. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01480-24

Duncan, C. L., Muther, E. F., Lindwall, J. J., Durkin, K., Ruvalcaba, E., Williamson, E., Ahrabi-Nejad, C., Bord, E., Green, A., Harrison, M. L., & Polineni, D. (2025). Using Community Engagement to Create a Telecoaching Intervention to Improve Self-Management in Adolescents and Young Adults With Cystic Fibrosis: Qualitative Study. Journal of Participatory Medicine, 17, e49941. https://doi.org/10.2196/49941

Keating, C., Yonker, L. M., Vermeulen, F., Prais, D., Linnemann, R. W., Trimble, A., Kotsimbos, T., Mermis, J., Braun, A. T., O’Carroll, M., Sutharsan, S., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Floreth, T., Michelson, P., Sosnay, P. R., … Horsley, A. (2025). Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00411-9

Nanaware, P. P., Khan, Z. N., Clement, C. C., Shetty, M., Mota, I., Seltzer, E. S., Dzieciatkowska, M., Gamboni, F., D’Alessandro, A., Ng, C., Nagayama, M., Lichti, C. F., Soni, R. K., Jacob B. Geri, Matei, I., Lyden, D., Longman, R., Lu, T. T., Wan, X., … Santambrogio, L. (2024). Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load. Cell Reports, 43(6), 114311. https://doi.org/10.1016/j.celrep.2024.114311

McDonald, C. M., Reid, E. K., Pohl, J. F., Yuzyuk, T. K., Padula, L. M., Vavrina, K., & Altman, K. (2024). Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy. Nutrition in Clinical Practice, 39(S1). Portico. https://doi.org/10.1002/ncp.11122

List, R., Solomon, G., Bichl, S., Horton, B. J., Shen, S., Corcoran, B., Sadeghi, H., Britto, M. T., Ren, C., & Albon, D. (2023). Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative. BMJ Open Quality, 12(4), e002466. https://doi.org/10.1136/bmjoq-2023-002466

Tervo, J. P., DiMango, E., Gudis, D. A., Keating, C., Zhang, Y., Leu, C., Altman, K., Vilarello, B., Jacobson, P., & Overdevest, J. B. (2023). Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy. International Forum of Allergy & Rhinology, 13(12), 2165–2171. Portico. https://doi.org/10.1002/alr.23209

Collins, M., Urban, M., Suleiman, M., Lapin, C., & Hopfer, S. (2023). 340 Decreasing time to definitive diagnosis in cystic fibrosis newborn screening. Journal of Cystic Fibrosis, 22, S169–S171. https://doi.org/10.1016/s1569-1993(23)01267-5

Goetz, D., Langfelder-Schwind, E., Kay, D., Sadeghi, H., DeCelie-Germana, J., Berdella, M., Soultan, Z., & Kier, C. (2023). 339 Diagnostic dilemmas in cystic fibrosis screen–positive infants with F191V and low sweat chloride. Journal of Cystic Fibrosis, 22, S169. https://doi.org/10.1016/s1569-1993(23)01266-3

Shah, M., Sadeghi, H., & Raissi, G. (2023). 706 Effect of highly effective modulator therapy on lipid profile of individuals with cystic fibrosis. Journal of Cystic Fibrosis, 22, S390. https://doi.org/10.1016/s1569-1993(23)01628-4

Hernandez-Trujillo, V., Zhou, C., Scalchunes, C., Ochs, H. D., Sullivan, K. E., Cunningham-Rundles, C., Fuleihan, R. L., Bonilla, F. A., Petrovic, A., Rawlings, D. J., & de la Morena, M. T. (2023). A Registry Study of 240 Patients with X-Linked Agammaglobulinemia Living in the USA. Journal of Clinical Immunology, 43(6), 1468–1477. https://doi.org/10.1007/s10875-023-01502-x

Izquierdo, M., Marion, C. R., Genese, F., Newell, J. D., O’Neal, W. K., Li, X., Hawkins, G. A., Barjaktarevic, I., Barr, R. G., Christenson, S., Cooper, C. B., Couper, D., Curtis, J., Han, M. K., Hansel, N. N., Kanner, R. E., Martinez, F. J., Paine, III, R., Tejwani, V., … Ortega, V. E. (2023). Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 199–210. https://doi.org/10.15326/jcopdf.2023.0388

Tzivelekis, S., Orange, J., Poulos, C., Meckley, L. M., Peay, H., Sutphin, J., Hernandez-Trujillo, V. P., & Wasserman, R. L. (2023). Development of A Novel Shared Decision Making Aid for Primary Immunodeficiency Diseases. Immunotherapy, 15(9), 647–656. https://doi.org/10.2217/imt-2022-0193

Uluer, A. Z., MacGregor, G., Azevedo, P., Indihar, V., Keating, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Rubenstein, R. C., Taylor-Cousar, J. L., Tullis, E., Yonker, L. M., Chu, C., Lam, A. P., Nair, N., Sosnay, P. R., Tian, S., Van Goor, F., … Wilson, J. (2023). Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. The Lancet Respiratory Medicine, 11(6), 550–562. https://doi.org/10.1016/s2213-2600(22)00504-5

Hill-Ricciuti, A., Walsh, E. E., Greendyke, W. G., Choi, Y., Barrett, A., Alba, L., Branche, A. R., Falsey, A. R., Phillips, M., Finelli, L., & Saiman, L. (2022). Clinical impact of healthcare-associated respiratory syncytial virus in hospitalized adults. Infection Control & Hospital Epidemiology, 44(3), 433–439. https://doi.org/10.1017/ice.2022.128

Motelow, J. E., Lippa, N. C., Hostyk, J., Feldman, E., Nelligan, M., Ren, Z., Alkelai, A., Milner, J. D., Gharavi, A. G., Tang, Y., Goldstein, D. B., & Kernie, S. G. (2022). Risk Variants in the Exomes of Children With Critical Illness. JAMA Network Open, 5(10), e2239122. https://doi.org/10.1001/jamanetworkopen.2022.39122

Gemmell, L. C., Giordano, J. L., Forman, E. J., & Brady, P. (2022). CLINICAL IMPLICATIONS OF EXPANDED CARRIER SCREENING (ECS) FOR FERTILITY CARE AND INDIVIDUAL HEALTH. Fertility and Sterility, 118(4), e18–e19. https://doi.org/10.1016/j.fertnstert.2022.08.071

Raraigh, K., Sheridan, M., Aksit, M., Pagel, K., Hetrick, K., Shultz-Lutwyche, H., Myers, B., Buckingham, K., Pace, R., Ling, H., Pugh, E., Knowles, M., Bamshad, M., Blackman, S., & Cutting, G. (2022). 152 My patient has an unresolved CFTR genotype … what next? Journal of Cystic Fibrosis, 21, S88–S89. https://doi.org/10.1016/s1569-1993(22)00843-8

Naehrig, S., Breuling, M., Mertsch, P., & Behr, J. (2022). 53 Pregnancies in women with cystic fibrosis with or without intake of elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis, 21, S32–S33. https://doi.org/10.1016/s1569-1993(22)00744-5

Ycaza, M., Keating, C., DiMango, E., Lopez, J., Saroya, T., & McNeill, T. (2022). 52 Participation in interventional drug trials of minority populations at an urban adult cystic fibrosis center. Journal of Cystic Fibrosis, 21, S32. https://doi.org/10.1016/s1569-1993(22)00743-3

Beswick, D., Overdevest, J., Zemke, A., Khatiwada, A., Gudis, D., Miller, J., Kimple, A., Smith, P., DiMango, E., Goralski, J., Keating, C., Stapleton, A., Balkissoon, C., & Taylor-Cousar, J. (2022). 574 Determining the minimal clinically important difference for the 22-question SinoNasal Outcome Test (SNOT-22) in people with cystic fibrosis. Journal of Cystic Fibrosis, 21, S319–S320. https://doi.org/10.1016/s1569-1993(22)01264-4

Zhong, G., Ahimaz, P., Edwards, N. A., Hagen, J. J., Faure, C., Lu, Q., Kingma, P., Middlesworth, W., Khlevner, J., El Fiky, M., Schindel, D., Fialkowski, E., Kashyap, A., Forlenza, S., Kenny, A. P., Zorn, A. M., Shen, Y., & Chung, W. K. (2022). Identification and validation of candidate risk genes in endocytic vesicular trafficking associated with esophageal atresia and tracheoesophageal fistulas. Human Genetics and Genomics Advances, 3(3), 100107. https://doi.org/10.1016/j.xhgg.2022.100107

El-Sayed, Z. A., El-Ghoneimy, D. H., Ortega-Martell, J. A., Radwan, N., Aldave, J. C., Al-Herz, W., Al-Nesf, M. A., Condino-Neto, A., Cole, T., Eley, B., Erwa, N. H. H., Espinosa-Padilla, S., Faria, E., Rosario Filho, N. A., Fuleihan, R., Galal, N., Garabedian, E., Hintermeyer, M., Imai, K., … Sullivan, K. (2022). Allergic manifestations of inborn errors of immunity and their impact on the diagnosis: A worldwide study. World Allergy Organization Journal, 15(6), 100657. https://doi.org/10.1016/j.waojou.2022.100657